Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × mCRPC × 90 days × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 108 Breast Neoplasms 106 Prostatic Neoplasms 55 Neoplasms 49 Multiple Myeloma 46 Lung Neoplasms 34 Parkinson Disease 4, Autosomal Dominant Lewy Body 32 Colorectal Neoplasms 32 Neoplasm Metastasis 30 Ovarian Neoplasms 28 Stomach Neoplasms 24 Urinary Bladder Neoplasms 23 Myasthenia Gravis 23 Leukemia, Lymphocytic, Chronic, B-Cell 23 Squamous Cell Carcinoma of Head and Neck 22 Leukemia, Myeloid, Acute 22 Lymphoma, Follicular 21 Carcinoma, Hepatocellular 21 Recurrence 19 Melanoma 19 Lymphoma, Large B-Cell, Diffuse 18 Carcinoma, Renal Cell 18 Small Cell Lung Carcinoma 17 Brain Neoplasms 17 Endometrial Neoplasms 16 Colonic Neoplasms 16 Lymphoma 14 Carcinoma 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 13

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡